Collagenase (Wound Debridement)
Brand names: Santyl, Iruxol Mono
A topical enzymatic debriding agent derived from Clostridium histolyticum used to remove devitalised tissue from chronic wounds and burns.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Collagenase digests denatured collagen anchoring necrotic tissue to the wound bed, achieving selective enzymatic debridement while sparing viable tissue.
Prescribing in practice
- Its enzymatic activity is inactivated by certain heavy-metal antiseptics and acidic agents, so incompatible cleansers and dressings must be avoided around application.
- It is intended for debridement and does not treat established wound infection, which needs separate management.
- Transient local discomfort or erythema at the wound margin can occur.
Monitoring
Monitor the wound bed at dressing changes for progress of debridement, granulation and any peri-wound irritation or infection.
Counselling the patient
- This ointment helps remove dead tissue so the wound can heal.
- Some surrounding redness or mild discomfort can occur.
- Use only the cleansing products advised, as some can stop it working.
Evidence & guidelines
Enzymatic debridement with collagenase is an established alternative to sharp or autolytic debridement in chronic-wound and burn care.
Reference: BBA wound care guidelines; Wounds UK best practice; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.